Bayer reports mortality signal in Phase III of Xofigo in early CRPC

Bayer AG (Xetra:BAYN) said it will unblind early the Phase III ERA223 trial to treat metastatic castration-resistant prostate cancer (CRPC) after

Read the full 217 word article

User Sign In